Low-Level Lead Exposure, Metabolic Syndrome, and Heart Rate Variability: The VA Normative Aging Study

Sung Kyun Park,1 Joel Schwartz,1,2 Marc Weisskopf,1 David Sparrow,3 Pantel S. Vokonas,3 Robert O. Wright,1,2 Brent Coull,1 Huiling Nie,1,2 and Howard Hu1,2

1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; 3VA Normative Aging Study, Veterans Affairs Boston Healthcare System and the Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA; 4Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA

Exposure to lead is known to affect the cardiovascular system, even at low, general environmental levels. Many epidemiologic studies have shown an association between chronic low-level lead exposure and hypertension (Hu et al. 1996; Korrick et al. 1999; Nash et al. 2003) and cardiovascular disease (Cheng et al. 1998; Lustberg and Silbergeld 2002; Schwartz 1991). One possible mechanism for this association is interference in autonomic nerve control of the heart. Experimental studies have shown that lead can generate reactive oxygen species (ROS) by depletion of glutathione and protein-bound sulfhydryl groups, leading to oxidative stress (Gurer and Ercal 2000). Oxidative stress plays an important role in the production of proinflammatory mediators, lipid peroxidation, the suppression of nitric oxide, and alteration of calcium homeostasis, which may increase central sympathetic nerve activity and reduce baroreflex sensitivity and vagal parasympathetic tone (Ding et al. 2000; Durum et al. 2005; Vaziri 2002).

Heart rate variability (HRV) is a non-invasive and quantitative marker of cardiac autonomic function that reflects the regulation of the sinoatrial node by the sympathetic and parasympathetic branches of the autonomic nervous system [Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (Task Force) 1996]. Decreased HRV is an independent predictor of mortality in middle-aged and elderly subjects, in patients with diabetes, and in survivors of myocardial infarction and other coronary heart diseases (Gerritsen et al. 1993; Teruya et al. 1991). A recent study from Korea on subjects occupationally exposed to lead showed significant univariate associations between blood lead and HRV measures, but failed to find the associations after adjustment for confounding variables, such as age, alcohol consumption, and other blood metal concentrations (Jhun et al. 2005).

In a community-based study of the relationship between bone lead and cardiac conduction among elderly men environmentally exposed to lead, our group previously found that higher bone lead levels were associated with electrocardiographic (ECG) features such as longer QT and QRS intervals and intraventricular and atrioventricular conduction defects, suggesting depressed cardiac conduction (Cheng et al. 1998). This could be evidence that even low-level exposure to lead may alter autonomic activity, because cardiac conduction is mediated, in part, through a branch of the autonomic nervous system (Ahnve and Vallin 1982).

Another issue in the study of lead toxicity is the identification of susceptible population groups, such as those with preexisting cardiovascular conditions. For example, people with metabolic syndrome (MetS), a cluster of health risks including obesity, diabetes, hypertension, and dyslipidemia (Moller and Kaufman 2005), are at greater risk of cardiovascular disease because they are likely to have stronger levels of oxidative-stress–induced inflammatory responses. As a result, they may be less able to homeostatically control responses to additional oxidative stressors such as lead exposure and therefore show more pronounced responses. Recently, Tsaih et al. (2004) observed that lead had a more pronounced effect on renal function in people with diabetes and hypertension. However, to
our knowledge, no previous study has examined modifications of the association between lead exposure and HRV by clinical conditions, such as MetS, diabetes, and hypertension.

In this study we examined the association of low-level lead exposure (measured in bone) with alterations in HRV among community residents with no previously known heavy lead exposure. We also assessed effect modifications by MetS and its individual components.

Materials and Methods

Study population. The Normative Aging Study is a longitudinal study established by the Veterans Administration (VA; now the U.S. Department of Veterans Affairs) in 1963, when 2,280 community-dwelling men from the Greater Boston area 21–80 years of age were enrolled (Bell et al. 1972). All participants were free of known chronic medical conditions at enrollment. Every 3–5 years, participants underwent physical examination such as assessment of body mass index (BMI) and measurement of systolic and diastolic blood pressures. During these visits, participants filled out questionnaires on cigarette smoking, food frequency, and various health risk factors. In addition, data on fasting blood glucose, total cholesterol, and high-density lipoprotein (HDL) cholesterol were also obtained from blood samples. Participants visited the study center in the morning after an overnight fast and abstinence from smoking.

From 1991 to 2002, Normative Aging Study participants who gave their informed consent were invited to undergo bone lead measurements. If subjects had more than one bone lead measurement during this period (75% of subjects analyzed; mean = 1.7, maximum = 4), the measurement closest to the date of the HRV measurement was used for this analysis. In 98 subjects (23.7%), bone lead levels were measured after the HRV measures were obtained. However, all of those bone lead measurements were obtained within 6 months of the HRV measurement. Because half-lives of tibia lead and patella lead are years to decades, we do not think that bone lead levels at the time of HRV measurement would have been different from those actually measured. In an earlier analysis, no important differences were detected between Normative Aging Study participants who did and did not have bone lead measurements taken (Cheng et al. 1998).

Beginning in November 2000, HRV measurement was added to the tests performed during the regular visits of Normative Aging Study subjects. Among active cohort members, 671 persons were examined for HRV from 14 November 2000 to 22 December 2004. Excluded were 110 subjects (16.4%) with problematic heart rate measurements, including atrial fibrillation, atrial bigeminy or trigeminy, pacemakers, irregular rhythm, irregular sinus rhythm, frequent ventricular ectopic activity, ventricular bigeminy, multifocal atrial tachycardia, or measurement time < 3.5 min. We further excluded 131 and 142 subjects without tibia or patella lead measurements, respectively; 10 subjects with high bone lead measurement uncertainties (≥10 µg/g and 15 µg/g for tibia and patella, respectively); 5 and 9 subjects with extreme tibia and patella lead levels, respectively; and 2 subjects with missing values of the potential confounding factors. Hence, 413 (tibia) and 398 (patella) subjects were available for lead analyses. All participants had given written informed consent. This study was reviewed and approved by the institutional review boards of all participating institutions.

HRV measurement. HRV was measured between 0600 and 1300 hours using a two-channel (five-lead) ECG monitor (Trillium 3000; Forest Medical, East Syracuse, NY). After the participants had rested for 5 min, the ECG was recorded (sampling rate of 256 Hz/channel) for approximately 7 min with the subject seated. We used the best 4-consecutive-min interval for the HRV calculations. The ECG digital recordings were processed, and heart rate and HRV measures were calculated using PC-based software (Trillium 3000 PC Companion Software for MS Windows; Forest Medical), which conforms to established guidelines (Task Force 1996). Beats were automatically detected and assigned tentative annotations, which were then reviewed by an experienced scanner to correct for any mislabeled beats or artifacts. We used only normal-to-normal (NN) beat intervals in the analysis; SD of NN intervals (SDNN) was calculated. We also computed high frequency (HF; 0.15–0.4 Hz), low frequency (LF; 0.04–0.15 Hz), and LF/HF ratio. HF and LF were also included as normalized units (HFnorm and LFnorm), which reflect the relative value of each power component in proportion to the total power minus the very low frequency component. An example of time domain R–R interval data and the estimate of power spectral density is shown in Figure 1. Spectral analysis of the time domain transforms the signal from time to frequency on the x-axis using a Fast Fourier transformation, by representing the signal as a combination of sine and cosine waves, with different amplitudes and frequencies. Table 1 describes various HRV parameters measured in this study. HF represents an estimate of parasympathetic (vagal) activity. The interpretation of LF is more controversial. Some studies consider LF,
when expressed in normalized units, to be a marker of sympathetic modulations, and other studies regard LF as reflecting both sympathetic and vagal activity. Consequently, LF/HF represents an estimate of sympathovagal balance or the sympathetic modulation (Task Force 1996). For simplicity, we present only the results for HF\text{norm}, LF\text{norm}, and LF/HF, which explain associations with the sympathetic and vagal modulations of the heart. Room temperature where the HRV measurement was taken was also recorded.

**Bone lead measurements.** Bone lead levels were measured at the midtibial shaft and the patella using a K-shell X-ray fluorescence (KXRF) instrument (ABIOMED, Danvers, MA). The physical principles, technical specifications, and validation of this instrument have been described in detail (Burger et al. 1990). The tibia and patella were targeted for bone lead research because they consist mainly of pure cortical and pure trabecular bone, respectively, and thus represent the two main bone compartments. Lead in trabecular bone has a faster turnover rate and therefore reflects more recent exposure than that in cortical bone. The KXRF instrument provides an unbiased estimate of bone lead levels (normalized for bone mineral content as micrograms of lead per gram of bone mineral) and an estimate of the uncertainty associated with each measurement.

Most bone lead measurements were obtained before the HRV measurement (median, 3.2 years). Kim et al. (1997) reported that an individual’s patella bone lead decreased by 23% over a 3-year follow-up in this same population (7.67% decrease/year), but tibia lead levels did not change. To account for the declining trend in patella lead levels, we predicted estimated patella lead levels as

\[ \text{Patella lead \times (1 – 0.0767)} \times (1 – 0.0767)^{d} \]

where \( d \) denotes the difference in years between dates of bone lead and HRV measurement.

**MetS and individual metabolic abnormalities.** We used the criteria of the National Cholesterol Education Program Adult Treatment Panel III (Ford et al. 2002; Moller and Kauffman 2005) and defined subjects having three or more of the following criteria as having MetS: \( a \) abdominal obesity (waist circumference \( \geq 102 \) cm in men; \( b \) hypertriglyceridemia (\( \geq 150 \) mg/dL); \( c \) low HDL cholesterol (< 40 mg/dL in men); \( d \) high blood pressure (\( \geq 130/85 \) mm Hg); and \( e \) high fasting glucose (\( \geq 110 \) mg/dL). We counted subjects who reported currently using hypertension or diabetes medication as having high blood pressure or high fasting glucose, respectively. Subjects whose waist circumference measurement was missing (\( n = 13 \)) were counted as having abdominal obesity if their BMI was \( \geq 30 \) kg/m\(^2\).

To investigate effect modifications by individual components of the MetS, we used stricter definitions. Diabetes was defined as fasting blood glucose of \( \geq 126 \) mg/dL, a physician’s diagnosis of type 2 diabetes, and/or use of a diabetes medication (e.g., oral hypoglycemic drug, metformin, or insulin). Hypertension was defined as reported use of hypertension medication, systolic blood pressure of \( \geq 160 \) mm Hg, or diastolic blood pressure of \( \geq 90 \) mm Hg. Because the prevalence of high blood pressure was relatively high in this population (67%), these high cutoff points were chosen to maintain a high degree of specificity among those subjects assigned as hypertensive (Hu et al. 1996). Abdominal obesity was defined as waist circumference \( \geq 106 \) cm (75th percentile). Dyslipidemia was defined as hypertriglyceridemia (triglyceride of \( \geq 150 \) mg/dL) and low HDL cholesterol levels (< 40 mg/dL).

**Statistical methods.** Extreme outliers in bone lead measures were identified and removed using the generalized extreme studentized deviation many-outlier method (Rosner 1983), as in previous analyses (Hu et al. 1996). To evaluate the linear regression assumption, penalized splines were used to allow the

<table>
<thead>
<tr>
<th>Table 2. Characteristics of study population according to the number of metabolic abnormalities.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study participants</strong></td>
</tr>
<tr>
<td><strong>Bone lead (median [IQR])</strong></td>
</tr>
<tr>
<td>Tibia lead (µg/g)</td>
</tr>
<tr>
<td>Patella lead (µg/g)</td>
</tr>
<tr>
<td>Estimated patella lead (µg/g)</td>
</tr>
<tr>
<td><strong>Continuous variables (mean ± SD)</strong></td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Body mass index (kg/m(^2))</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
</tr>
<tr>
<td>Fasting blood glucose (mg/dL)</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
</tr>
<tr>
<td>High density lipoprotein (mg/dL)</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
</tr>
</tbody>
</table>

| **Categorical variables (%)** | | | | |
| Smoking status | | | | |
| Never-smoker | 31.2 | 38.3 | 30.9 | 28.6 |
| Former smoker | 63.2 | 55.0 | 64.1 | 65.4 |
| Current smoker | 5.6 | 6.7 | 5.0 | 6.0 |
| Alcohol intake (≥ 2 drinks/day) | | | | |
| 19.4 | 18.3 | 22.7 | 14.3 |
| Diabetes mellitus | 20.6 | 0.0 | 10.9 | 45.8* |
| Ischemic heart disease history | 29.1 | 0.0 | 34.7 | 25.3* |
| Stroke history | 6.3 | 0.0 | 6.8 | 8.3* |
| Hypertension | 70.9 | 11.7 | 76.8 | 88.0* |
| Use of β-blocker | 34.6 | 0.0 | 36.4 | 47.4* |
| Use of α-channel blocker | 14.0 | 0.0 | 14.1 | 20.3* |
| Use of ACE inhibitor | 21.3 | 0.0 | 22.3 | 29.3 |
| Use of statin | 37.1 | 20.0 | 35.0 | 48.1* |

**HRV [mean (median)]**

- **SDNN (msec)**: 38.8 (34.0) 39.8 (35.5) 40.7 (35.0) 35.2 (30.0)
- **HF (msec\(^2\)**): 290.1 (71.0) 268.0 (79.0) 346.1 (67.5) 207.4 (71.0)
- **LF (msec\(^2\)**): 193.5 (96.0) 194.0 (117.5) 213.8 (100.0) 159.7 (83.0)
- **HF norm (µu)**: 45.8 (41.8) 44.0 (40.1) 45.0 (39.7) 48.0 (47.4)
- **LF norm (µu)**: 54.2 (59.2) 56.1 (59.9) 55.0 (60.3) 51.9 (52.9)
- **LF/HF**: 2.1 (1.4) 2.2 (1.5) 2.2 (1.5) 1.8 (1.1)

| Abdominal obesity, hypertriglyceridemia, low HDL cholesterol, high blood pressure, and high fasting glucose. \( p_1 = 398 \).
| Patella lead \xrightarrow{(1 – 0.0767)} \text{difference in years between dates of bone lead and HRV measurement}. \( p_2 = 400 \). \( \text{For trend} < 0.05 \).
relation between the exposure and response to be more flexible (Eilers and Marx 1996). This smoothing method makes no assumptions regarding the shape of the association (Wood 2006). The penalized splines can be estimated in a generalized additive model using R software (R Foundation for Statistical Computing 2006). The optimal degree of smoothing was determined by the generalized cross-validation criterion, which is, in practice, an approximation of Akaike’s information criterion (Wood 2000).

Results

Table 2 shows the demographic and clinical characteristics and HRV measurements of the participants. All the study participants were male, with a mean (± SD) age of 72.9 ± 6.5 years. The median tibia and patella lead levels were 19 µg/g (IQR, 11–28 µg/g) and 23 µg/g (IQR, 15–34 µg/g), respectively. After adjusting for the decreasing trend of patella lead levels, the estimated median was reduced (16.3 µg/g; IQR, 10.4–25.8 µg/g). Hereafter, we refer to the estimated value as “patella lead.” The correlation between tibia and patella lead was high (Spearman correlation coefficient = 0.54). Of the subjects, 133 (32%) were identified as having MetS. BMI, waist circumference, systolic blood pressure, fasting glucose, total cholesterol, HDL, and triglyceride were determined as having MetS. BMI, waist circumference of Akaike’s information criterion (Wood 2006). The optimal degree of smoothing was determined by the generalized cross-validation criterion, which is, in practice, an approximation of Akaike’s information criterion (Wood 2000).

Table 3. Prevalence of individual metabolic abnormalities and MetS in the Normative Aging Study.

<table>
<thead>
<tr>
<th>Abdominal obesity</th>
<th>Hypertroglucidemia</th>
<th>Low HDL cholesterol</th>
<th>High blood pressure or medication use</th>
<th>High fasting glucose or medication use</th>
<th>MetS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (%)²</td>
<td>35.8</td>
<td>26.4</td>
<td>25.4</td>
<td>66.8</td>
<td>33.4</td>
</tr>
<tr>
<td>Tertile of age-adjusted tibia lead (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 14.1 µg/g (n = 138)</td>
<td>36.2</td>
<td>22.5</td>
<td>23.2</td>
<td>64.5</td>
<td>33.3</td>
</tr>
<tr>
<td>14.1–23.8 µg/g (n = 132)</td>
<td>37.2</td>
<td>25.4</td>
<td>24.8</td>
<td>60.9</td>
<td>29.7</td>
</tr>
<tr>
<td>&gt; 23.8 µg/g (n = 137)</td>
<td>35.0</td>
<td>31.4</td>
<td>28.5</td>
<td>75.2</td>
<td>37.2</td>
</tr>
<tr>
<td>ρ for trend</td>
<td>0.84</td>
<td>0.09</td>
<td>0.32</td>
<td>0.06</td>
<td>0.50</td>
</tr>
<tr>
<td>ρ for trend</td>
<td>10.2</td>
<td>12.8</td>
<td>13.1</td>
<td>65.9</td>
<td>31.1</td>
</tr>
<tr>
<td>&gt; 22.2 µg/g (n = 133)</td>
<td>36.8</td>
<td>29.3</td>
<td>24.1</td>
<td>63.9</td>
<td>35.3</td>
</tr>
<tr>
<td>ρ for trend</td>
<td>0.07</td>
<td>0.15</td>
<td>0.12</td>
<td>0.86</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Table 4. The estimated change (95% CI) in HRV parameters associated with one IQR increase in bone lead markers.

<table>
<thead>
<tr>
<th>Tibia</th>
<th>No.</th>
<th>Hfnorm (µu)</th>
<th>Lfnorm (µu)</th>
<th>Log10 LFHF (%)</th>
<th>Patella</th>
<th>No.</th>
<th>Hfnorm (µu)</th>
<th>Lfnorm (µu)</th>
<th>Log10 LFHF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>413</td>
<td>–1.1 (–4.1 to 1.9)</td>
<td>1.2 (–1.8 to 4.2)</td>
<td>4.6 (–9.8 to 21.3)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.9 to 16.5)</td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>413</td>
<td>–0.9 (–3.9 to 2.1)</td>
<td>0.9 (–2.0 to 3.9)</td>
<td>3.3 (–10.7 to 19.5)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.7 to 16.2)</td>
<td></td>
</tr>
<tr>
<td>Model 2</td>
<td>413</td>
<td>–0.9 (–3.9 to 2.1)</td>
<td>0.9 (–2.0 to 3.9)</td>
<td>3.3 (–10.7 to 19.5)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.7 to 16.2)</td>
<td></td>
</tr>
<tr>
<td>No. of metabolic abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>60</td>
<td>–3.8 (–12.5 to 4.9)</td>
<td>4.0 (–8.4 to 12.7)</td>
<td>22.6 (–20.3 to 88.4)</td>
<td>60</td>
<td>3.7 (–3.8 to 11.2)</td>
<td>–3.5 (–11.0 to 4.0)</td>
<td>–16.1 (–41.7 to 20.8)</td>
<td></td>
</tr>
<tr>
<td>1–2</td>
<td>220</td>
<td>0.1 (–3.7 to 3.9)</td>
<td>–0.3 (–3.9 to 3.8)</td>
<td>–3.0 (–19.7 to 17.2)</td>
<td>209</td>
<td>0.7 (–2.6 to 4.0)</td>
<td>–0.8 (–4.1 to 2.5)</td>
<td>–3.4 (–17.8 to 13.4)</td>
<td></td>
</tr>
<tr>
<td>≥ 3</td>
<td>133</td>
<td>–2.7 (–7.9 to 2.5)</td>
<td>2.7 (–2.5 to 7.9)</td>
<td>15.6 (–10.5 to 49.4)</td>
<td>129</td>
<td>–3.9 (–8.2 to 0.5)</td>
<td>3.9 (–0.4 to 8.3)</td>
<td>21.2 (–1.9 to 49.8)</td>
<td></td>
</tr>
<tr>
<td>ρ for trend</td>
<td>0.86</td>
<td>0.92</td>
<td>0.808</td>
<td>0.048</td>
<td>0.047</td>
<td>0.045</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IQR increase: 17 µg/g for tibia lead and 15.4 µg/g for patella lead. Model 1: adjusted for age, cigarette smoking, alcohol consumption, room temperature, and season. Model 2: further adjusted for BMI; fasting glucose; HDL cholesterol; triglyceride; and use of β-blockers, calcium channel blockers, and/or ACE inhibitors.

Table 5. The estimated change (95% CI) in HRV parameters associated with one IQR increase in bone lead markers.

<table>
<thead>
<tr>
<th>Tibia</th>
<th>No.</th>
<th>Hfnorm (µu)</th>
<th>Lfnorm (µu)</th>
<th>Log10 LFHF (%)</th>
<th>Patella</th>
<th>No.</th>
<th>Hfnorm (µu)</th>
<th>Lfnorm (µu)</th>
<th>Log10 LFHF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>413</td>
<td>–1.1 (–4.1 to 1.9)</td>
<td>1.2 (–1.8 to 4.2)</td>
<td>4.6 (–9.8 to 21.3)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.9 to 16.5)</td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>413</td>
<td>–0.9 (–3.9 to 2.1)</td>
<td>0.9 (–2.0 to 3.9)</td>
<td>3.3 (–10.7 to 19.5)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.7 to 16.2)</td>
<td></td>
</tr>
<tr>
<td>Model 2</td>
<td>413</td>
<td>–0.9 (–3.9 to 2.1)</td>
<td>0.9 (–2.0 to 3.9)</td>
<td>3.3 (–10.7 to 19.5)</td>
<td>398</td>
<td>–0.6 (–3.1 to 1.9)</td>
<td>0.6 (–1.9 to 3.1)</td>
<td>3.0 (–8.7 to 16.2)</td>
<td></td>
</tr>
<tr>
<td>No. of metabolic abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>60</td>
<td>–3.8 (–12.5 to 4.9)</td>
<td>4.0 (–8.4 to 12.7)</td>
<td>22.6 (–20.3 to 88.4)</td>
<td>60</td>
<td>3.7 (–3.8 to 11.2)</td>
<td>–3.5 (–11.0 to 4.0)</td>
<td>–16.1 (–41.7 to 20.8)</td>
<td></td>
</tr>
<tr>
<td>1–2</td>
<td>220</td>
<td>0.1 (–3.7 to 3.9)</td>
<td>–0.3 (–3.9 to 3.8)</td>
<td>–3.0 (–19.7 to 17.2)</td>
<td>209</td>
<td>0.7 (–2.6 to 4.0)</td>
<td>–0.8 (–4.1 to 2.5)</td>
<td>–3.4 (–17.8 to 13.4)</td>
<td></td>
</tr>
<tr>
<td>≥ 3</td>
<td>133</td>
<td>–2.7 (–7.9 to 2.5)</td>
<td>2.7 (–2.5 to 7.9)</td>
<td>15.6 (–10.5 to 49.4)</td>
<td>129</td>
<td>–3.9 (–8.2 to 0.5)</td>
<td>3.9 (–0.4 to 8.3)</td>
<td>21.2 (–1.9 to 49.8)</td>
<td></td>
</tr>
<tr>
<td>ρ for trend</td>
<td>0.86</td>
<td>0.92</td>
<td>0.808</td>
<td>0.048</td>
<td>0.047</td>
<td>0.045</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IQR increase: 17 µg/g for tibia lead and 15.4 µg/g for patella lead. Model 1: adjusted for age, cigarette smoking, alcohol consumption, room temperature, and season. Model 2: further adjusted for BMI; fasting glucose; HDL cholesterol; triglyceride; and use of β-blockers, calcium channel blockers, and/or ACE inhibitors.

*All models adjusted as model 1. *p < 0.1.
discussed in persons with hypertension, whereas it
increased by 2.7 µg/L (95% CI, 1.5 to 7.0 µg/L)
in persons without hypertension. Similarly,
the same groups of participants, one IQR
increase in patella lead was associated with a
13.0% (95% CI, 2.4 to 50.8%) change in
LF/HF among subjects with hypertension and a
–12.9% (95% CI, –29.2 to 7.0%) change in
LF/HF among those without hypertension.
In addition, higher patella lead was consistently
associated with lower HF
 and higher
LF norm, and LF/HF among obese or diabetic
persons. However, the associations were not
significant whether persons had those condi-
tions or not, and interactions were not statisti-
cally significant. We also examined whether obesity, ischemic heart disease, use of statin,
or use of antihypertensive medication, such as
β-blockers and calcium channel blockers,
modified the effects of bone lead on HRV,
but no statistically significant interaction was
observed (data not shown).

Discussion
Results of the present study suggest that persons
with multiple metabolic abnormalities are
subject to significantly stronger effects from
cumulative lead exposure, as reflected in patella
bone, on a reduction in HF
, a marker of
parasympathetic (vagal) nerve activity, and on
elevations in LF norm, a marker of sympathetic
activity, and LF/HF ratio, a marker of sympa-
thetic-vagal balance. These associations became
gradually stronger as the number of metabolic
abnormalities increased. We also observed
subjects with MetS or individual components
were consistently more affected by patella lead
than those without MetS or individual compo-
ents. Elevated LF/HF reflects sympathetic
excitation and parasympathetic withdrawal,
which may be linked with cardiac events such as
ventricular arrhythmias and myocardial
infarction (Task Force 1996). When the
cohort was not stratified by number of meta-
abolic abnormalities, trends were in the
expected direction but were not statistically
significant, presumably because of the direc-
tion of the association among people without
metabolic abnormalities being opposite to the
association among people with MetS.

The biologic mechanisms that link lead
exposure with alterations in the autonomic
nervous system are not well understood.
Redox-inactive metals such as lead deplete
 glutathione and protein-bound sulphydryl
groups, resulting in the production of ROS
such as hydroxyl radicals, because lead has a
high affinity for sulphydryl groups (Gurer and
Ercal 2000). Many studies have confirmed
that lead exposure is associated with lipid per-
oxidation, alterations in antioxidant enzyme
activities such as superoxide dismutase and
 glutathione peroxidase, and DNA damage
(Fracasso et al. 2002; Oktem et al. 2004; Sandhir and Gill 1995; Ye et al. 1999).

Oxidative stress is known to produce pro-
flammatory mediators, inhibit nitric oxide,
and alter calcium homeostasis, which may be
linked with sympathetic excitation and vagal
withdrawal (Ding et al. 2000; Dursun et al.
2005; Vaziri 2002). Lead modifies the intra-
cellular calcium messenger system and disturbs
calcium homeostasis because lead mimics cal-
cium and enters cells via calcium channels
(Kober and Cooper 1976; Sandhir and Gill
1994). Lead exposure down-regulates nitric
oxide production (Vaziri 2002), which causes
an increase in sympathetic and a reduction in
vagal activity (Chowdhary et al. 2002).

Conflicting results were reported in stud-
ies of workers occupationally exposed to lead.
Studies of male workers with above-average
blood lead levels (average ~ 35 µg/dL) found
significantly diminished vagal activity as
measured by the coefficient of variation in
R–R intervals compared with nonexposed
controls at rest (Murata and Araki 1991;
Murata et al. 1993) and during deep breath-
ing (Teruya et al. 1991), whereas no associa-
tion was found among battery workers with
mean blood lead of 51 µg/dL (Gennart et
1992). These conflicting results may be due
to different geographical areas and age groups
studied, or because investigators did not con-
sider potential effect modification by the
underlying oxidative stress, such as metabolic
syndrome.

MetS, also known as syndrome X or
insulin resistance syndrome, is a set of cardio-
vascular risks that increases the likelihood of
developing type 2 diabetes, hypertension, and
coronary artery disease (Moller and Kaufman
2005). From analysis based on the National
Health and Nutrition Examination Survey III
data, the age-adjusted prevalence of MetS was
24% overall and 42% among those ≥70
years of age (Ford et al. 2002). An estimated 47
million U.S. residents have MetS based on 2000
census data (Ford et al. 2002). Several large
prospective studies have shown associations
between MetS and increased risks of cardio-
vascular disease as well as all-cause mortality
(Ford 2005; Malik et al. 2004). In the present
study, approximately 32% of the participants
(mean age 73 years) had MetS; this relatively
low prevalence probably reflects the predomi-
nant white population of the Normative Aging
Study cohort.

MetS is known to be associated with low
HRV (Hemingway et al. 2005; Liao et al.
1998; Pikkujamsa et al. 1998). This is likely
because people with MetS tend to have a
greater percentage of adipose tissue (related to
insulin resistance, glucose intolerance, and
increased inflammation), atherogenic dyslipi-
demia, hypertension, and a higher proinflam-
matory and prothrombotic state, all of which

![Figure 2. Associations of the HRV measures HF norm (A,B), LF norm (C,D) and log LF/HF (E,F) with tibia lead (A,C,E) and patella lead (B,D,F) adjusted for age, BMI, fasting glucose, HDL, triglyceride, cigarette smoking, alcohol consumption, use of β-blockers, calcium channel blockers, and/or ACE inhibitors, room temperature, and season. The solid line indicates the nonparametric trends estimated from the penalized spline method, and the dotted lines indicate its 95% CIs. The optimal degree of smoothing determined by the generalized cross-validation criterion for all HRV measures was 1, which means the associations were nearly linear.](image-url)
are associated with decreased parasympathetic and increased sympathetic tone (Moller and Kaufman 2005). A possible explanation of our results is that the combined oxidative stress and resulting overexposure to ROS caused by long-term exposure to lead and MetS increases the risk of autonomic dysfunction. The observed significant interaction between hypertension and patella lead levels in relation to HRV may have a similar explanation: hypertension is associated with depressed HRV (Schroeder et al. 2003; Singh et al. 1998) and has been shown to modify the association between HRV and other ROS-generating factors, such as particulate matter (Park et al. 2005). Nonstatistically significant but consistent alterations in HRV measures only among persons with diabetes or abdominal obesity support the contention that proinflammatory conditions play a role in susceptibility to the autonomic impact of lead exposure.

We found that patella lead, but not tibia lead, had interactive effects with MetS on HRV. This differential sensitivity may be due to different lead kinetics in the two types of bone, cortical (tibia) bone and trabecular (patella) bone. Because the half-life of lead is decades in the tibia and only a few years in the patella, tibia lead reflects long-term cumulative lead exposure, whereas patella lead indicates the predominant skeletal source of circulating lead (Hu et al. 1998). Because patella lead is a more readily mobilizable bone source of lead than tibia lead, it may be a better marker in the association with HRV.

We could not evaluate the association between blood lead and HRV because most blood lead measurements among the Normative Aging Study participants were not obtained at the time of HRV measurement; thus, those levels could not be presumed to be a marker of lead exposure at the time of HRV measurement. As discussed above, several studies have shown an association between blood lead and alterations in autonomic function among occupationally exposed subjects with very high blood lead levels (Bockelmann et al. 2002; Murata and Araki 1991; Murata et al. 1993; Teruya et al. 1991). Therefore, further studies of the relationship between blood lead and HRV in a general population not occupationally exposed to lead are needed to determine whether contemporary exposure to lead is an important predictor of autonomic dysfunction.

The present study has several limitations. Although we collected information on many factors that might influence autonomic nervous system function, those factors could not account for all the variation in HRV. However, we tried to control for many potential confounding factors including age, BMI, blood glucose, cigarette smoking, and alcohol consumption. We controlled for blood lipid profiles (HDL and triglyceride), although these did not change the associations we observed because these variables account for some variance in HRV. We measured the ECG at a stable temperature and adjusted for the temperature of the room where the ECG was taken. Additionally, we adjusted for season, because HRV indexes of healthy men vary physiologically by season, with lowest values in the winter (Kristal-Boneh et al. 2000). Therefore, the observed findings are less likely to reflect bias due to these confounding factors.

We analyzed subjects who had bone lead levels available (approximately 77% of all Normative Aging Study subjects who had ECG measurements). However, our research group has previously found no important differences between Normative Aging Study participants who did and did not have bone lead levels available (Cheng et al. 1998). Therefore, we believe that the participants of this study represent the entire cohort.

In addition, the Normative Aging Study cohort is all male and almost all white. Thus, while sex and race cannot bias our results (both are known to be important determinants of HRV), the results of this study may not be generalizable to females or nonwhite ethnic populations.

This population-based study supports the hypotheses that the autonomic effects of cumulative lead exposure become gradually stronger with the number of metabolic abnormalities and that elderly men with individual components of MetS are more susceptible to cardiac autonomic dysfunction (as measured by HRV) in association with chronic lead exposure as measured in patella. The modification by MetS could be consistent with the hypothesis that the oxidative stress response is an important mechanism by which lead toxicity affects the cardiovascular system.

**REFERENCES**


